2016
DOI: 10.1001/jamaoncol.2015.5511
|View full text |Cite
|
Sign up to set email alerts
|

Precision Medicine and Low- to Middle-Income Countries

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
18
0

Year Published

2017
2017
2023
2023

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 23 publications
(18 citation statements)
references
References 9 publications
0
18
0
Order By: Relevance
“…In addition, while genetic‐based targeted cancer therapy is emerging, histological tumor subtyping is more readily available in the vast majority of clinical settings . In turn, many patients may benefit from personalized treatment based on the histological tumor subtyping . In particular, several authors have reported that histological tumor subtype may be a reliable hallmark of the underlying genetic tumor characteristics and, in turn, have a role in predicting prognosis .…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition, while genetic‐based targeted cancer therapy is emerging, histological tumor subtyping is more readily available in the vast majority of clinical settings . In turn, many patients may benefit from personalized treatment based on the histological tumor subtyping . In particular, several authors have reported that histological tumor subtype may be a reliable hallmark of the underlying genetic tumor characteristics and, in turn, have a role in predicting prognosis .…”
Section: Discussionmentioning
confidence: 99%
“…[24][25][26][27] In turn, many patients may benefit from personalized treatment based on the histological tumor subtyping. [28][29][30][31] In particular, several authors have reported that histological tumor subtype may be a reliable hallmark of the underlying genetic tumor characteristics and, in turn, have a role in predicting prognosis. 5,6,8,18,32,33 To this end, we sought to define the prognostic impact of three frequent histological subtypes of colon cancer-"classic" (CA), mucinous (MUC), and signet-cell (SC) adenocar- Several limitations should be considered when interpreting the results.…”
Section: Propensity Score Matching Analysesmentioning
confidence: 99%
“…But even if there are findings derived from big data relevant to a particular subgroup, it may be that the costs or infrastructure required to deploy precision medicine interventions are prohibitive for them. Already, some are raising concerns about the high costs of targeted therapies (Ciardiello et al 2014;Goddard et al 2012;Ferkol and Quinton 2015); even if interventions come out favourably on a cost-benefit calculation, the high absolute costs of intervention may still exclude many, especially in countries that lack universal healthcare or have tight healthcare budgets (Rehman et al 2016). Ensuring adequate sharing of the benefits of precision medicine itself will be costly, however, and a push for generic or biosimilar therapeutics may be seen as overly aggressive if it disincentivizes high-income countries from investing in precision medicine.…”
Section: Balancing Of Interests/sharing Of Benefitsmentioning
confidence: 99%
“…Another study concluded that PM able to show a new way of treatment options for those diseases previously were not treatable. This further added that the amount of investment made by high-income countries for PM, a similar amount of investment by LMICs in developing PM is impossible 100 . One study reported that there five areas of difficulties regarding PM.…”
Section: Changeless Of Precision Medicine In Lowerand Middle-income Cmentioning
confidence: 99%